| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 5g | ||
| Other Sizes |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
14C-Cyproconazole (radiochemical purity >98%) was mixed with SAN 1414 F 360 SL 001 BS (6.41% w/w cyproconazole, 300 g/L disacyldimethylammonium chloride) to achieve a final nominal radioactive concentration of 1 μCi/18 mg, with nominal doses of 0.641, 0.01, or 0.0012 mg ai/cm². …The prepared test material was applied to isolated rat or human skin (1.77 cm²/sample) and placed in an in vitro skin permeation pool. Ten samples were processed for each tissue, and the results for the first five samples were reported. …The permeation rate of 14C-Cyproconazole after skin application was higher than that of human skin. The undiluted formulation permeated rat skin at a rate of 12.30 μg/cm²/h, while the permeation rate in human skin was 0.501 μg/cm²/h. Permeation rate decreased and permeability coefficient increased with increasing dilution factor. Metabolism/Metabolites…Cyproconazole is metabolized similarly in ruminants and poultry. The main metabolic pathways involve hydroxylation of the cyclopropyl carbon or elimination of the methylcyclopropyl chain, followed by reduction. Hydroxylation of the methyl group is also a major metabolic pathway, as are ring-opening and modification of the cyclopropyl ring. Data indicate limited cleavage of the triazole ring, with most residues retaining the intact phenyl and triazole rings. Cyproconazole (both free and bound) is the only significant (>10%) residue identified in plant metabolism studies (excluding triazole metabolites). |
|---|---|
| Toxicity/Toxicokinetics |
Non-Human Toxicity Values
Mice oral LD50: 352 mg/kg /from table/ Rats oral LD50: 1020 mg/kg (male) and 1330 mg/kg (female) Rats oral LD50: 1020 mg/kg /from table/ Rats oral LD50: 2054 mg/kg (male and female) For more complete non-human toxicity data for cyproconazole (8 types), please visit the HSDB record page. |
| Additional Infomation |
2-(4-Chlorophenyl)-3-cyclopropyl-1-(1H-1,2,4-triazol-1-yl)but-2-ol is a tertiary alcohol with a structure in which but-2-ol is substituted at the 2-position with a 4-chlorophenyl group, at the 3-position with a cyclopropyl group, and at the 1-position with a 1H-1,2,4-triazol-1-yl group. It belongs to the monochlorobenzene, tertiary alcohol, triazole, and Cyprodenate compounds. Cyproconazole 360 SL is a water-based wood preservative used to prevent fungal decay in above-ground timber. It is not suitable for protecting timber in contact with soil. If there is a risk of insect infestation, a registered insecticide should be used concurrently.
|
| Molecular Formula |
C15H18CLN3O2S
|
|---|---|
| Molecular Weight |
291.77
|
| Exact Mass |
291.114
|
| CAS # |
94361-06-5
|
| PubChem CID |
86132
|
| Appearance |
Colorless crystals from hexane/CH2Cl2
Colorless solid |
| Density |
1.32
|
| Boiling Point |
>250ºC
|
| Melting Point |
106.2-106.9ºC
|
| Flash Point |
>100 °C
|
| LogP |
2.865
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
20
|
| Complexity |
331
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=CC(C(C(C2CC2)C)(CN2C=NC=N2)O)=CC=1
|
| InChi Key |
UFNOUKDBUJZYDE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H18ClN3O/c1-11(12-2-3-12)15(20,8-19-10-17-9-18-19)13-4-6-14(16)7-5-13/h4-7,9-12,20H,2-3,8H2,1H3
|
| Chemical Name |
2-(4-chlorophenyl)-3-cyclopropyl-1-(1,2,4-triazol-1-yl)butan-2-ol
|
| Synonyms |
HSDB 7706; Atemi; Alto 100SL
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~342.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (8.57 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4274 mL | 17.1368 mL | 34.2736 mL | |
| 5 mM | 0.6855 mL | 3.4274 mL | 6.8547 mL | |
| 10 mM | 0.3427 mL | 1.7137 mL | 3.4274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
